Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Sickle Cell Disease ... It is formulated as concentrate for a solution and as an injection for ...

Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Coronavirus Disease ... It is formulated as concentrate for a solution and as an injection for ...

("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced it ...

The agreement involves NRx Pharmaceuticals, HOPE Therapeutics, Inc. (a wholly-owned subsidiary of NRx Pharmaceuticals), and JGS Holdings LLC, a Wyoming Limited Liability Company. The agreement ...

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Divalproex Sodium Delayed ...

HOPE Therapeutics and a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP) announced signing of a Binding Term Sheet with Smith & Sauer, LLC, for $25 million equity purchases to fund planned ...

HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced ...

(RTTNews) - HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NRXP), Monday announced the signing of a Binding Term Sheet of $27 million with Smith & Sauer, LLC. Of the total amount ...

Infinity Pharmaceuticals Inc. 0.00% $90.76 ...

2005;62(23):2410-2412. To increase the flexibility in preparation time and storage and decrease waste after reconstituting pantoprazole sodium for injection, it would be desirable to have a longer ...